Propafenone Hydrochloride NDC 0832-0740

NDC codes

FDA NDC Directory

Product NDC (as listed)0832-0740Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00832-0740Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0832-0740-60	00832074060	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0832-0740-60)Marketed from Jun 25, 2020

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Propafenone Hydrochloride
Generic name (nonproprietary): propafenone hydrochloride
Active ingredients: Propafenone hydrochloride — 225 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Upsher-Smith Laboratories, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 212744
Marketing start: Jun 25, 2020
Marketing end: Nov 30, 2026
Identifiers: Product ID 0832-0740_45afbac0-5c1a-ebc5-e063-6294a90a4d5eSPL ID 45afbac0-5c1a-ebc5-e063-6294a90a4d5eSPL set ID 8aa6f58a-2980-4caa-9c54-d55d69d5d132RxCUI 861156, 861164, 861171UNII 33XCH0HOCDUPC 0308320740607
Pharmacologic class: Antiarrhythmic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400832074060 followed by a unit qualifier and the quantity

Package 00832-0740-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 11, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Propafenone hydrochloride extended-release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. Propafenone hydrochloride extended-release capsules are an antiarrhythmic indicated to prolong the time to recurrence of symptomatic atrial fibrillation (AF) in patients with episodic (most likely paroxysmal or persistent) AF who do not have structural heart disease. ( 1 ) Usage Considerations: Use in patients with permanent atrial fibrillation or with atrial flutter or paroxysmal supraventricular tachycardia (PSVT) has not been evaluated. Do not…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 212744

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 212744
Product	Strength	Form · route	Labeler	Product NDC
Propafenone Hydrochloride	Propafenone hydrochloride 325 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0832-0741
Propafenone Hydrochloride	Propafenone hydrochloride 425 mg/1	Capsule, Extended releaseOral	Upsher-Smith Laboratories, LLC	0832-0742